Low rate of subsequent malignant neoplasms following CAR T-cell therapy-Reference-Cited by-同舟云学术

Low rate of subsequent malignant neoplasms following CAR T-cell therapy

Published:2022-07-14 Issue: Volume: Page:
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Hsieh Emily M¹,Myers Regina M²^ORCID,Yates Bonnie³,Annesley Colleen⁴,John Samuel⁵,Taraseviciute Agne⁶,Steinberg Seth M⁷,Sheppard Jennifer Dianne⁵,Chung Perry²,Chen Lee⁸,Lee Daniel W.⁹^ORCID,DiNofia Amanda²,Grupp Stephan A.¹⁰,Verneris Michael R¹¹,Laetsch Theodore W.¹²,Bhojwani Deepa⁸,Brown Patrick A.¹³^ORCID,Pulsipher Michael A⁶^ORCID,Rheingold Susan R.¹⁰^ORCID,Gardner Rebecca A⁴,Gore Lia¹⁴^ORCID,Shah Nirali N¹⁵^ORCID,Lamble Adam⁴

Affiliation:

1. Children's Hospital of Los Angeles, Los Angeles, California, United States

2. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

3. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

4. Seattle Children's Hospital, Seattle, Washington, United States

5. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States

6. Children's Hospital Los Angeles, United States

7. Biostatistics and Data Management Section, National Cancer Institute, NIH, Bethesda, Maryland, United States

8. Children's Hospital Los Angeles, Los Angeles, California, United States

9. National Cancer Institute/Center for Cancer Research, Pediatric Oncology Branch, NIH, United States

10. The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

11. University of Colorado, Denver, Aurora, Colorado, United States

12. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States

13. Bristol Myers Squibb, Cockeysville, Maryland, United States

14. Children's Hospital Colorado and University of Colorado Cancer Center, Aurora, Colorado, United States

15. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2022008093/1908784/bloodadvances.2022008093.pdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence;International Immunopharmacology;2024-10

2. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

3. Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype;Leukemia & Lymphoma;2024-08-08

4. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?;Cancer Letters;2024-08

5. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase;eClinicalMedicine;2024-07